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CO-PRODUCTION OF KNOWLEDGE
Rethinking research processes to strengthen 
co-production in low and middle income countries
Co-production needs to become an integral part of the training and funding of researchers to 
ensure research meets everyone’s needs, argue David Beran and colleagues
Global health research needs to include a greater diversity of stakeholders within the research process. Involving people who are not academics 
in the co-production of research has many 
potential benefits: generation of a wider 
range of ideas; including the needs of peo-
ple directly affected by the research; inclu-
sion of broader sets of skills and views, 
values, and epistemologies in designing 
projects; allowing dialogue, participative 
decision making processes throughout 
the development and delivery of research; 
ensuring uptake of research results; 
increasing legitimacy and acceptance; and 
assuring sustainability.1-5
However, co-production has its own 
challenges.1 6 7 For example, finding 
practical ways to collaborate with stake-
holders outside academia to prepare 
grant applications and proposals is a 
substantial challenge. The “negative” costs 
of co-production are described as the costs 
of actually doing co-production; personal 
and professional costs to the researcher; 
costs to participants; and costs to projects 
in general of this appraoch.7 Successful 
co-production requires the corresponding 
skills and appropriate tools and resources 
to include a wide variety of stakeholders. 
This in turn challenges current training, 
career progression pathways, and funding 
processes for researchers. Research 
funders are key to many of these and 
include government research councils or 
foundations, independent foundations, 
and government development agencies, 
particularly in low and middle income 
countries (LMICs). Stakeholders include 
people with a given health problem, 
community members, healthcare providers, 
civil society organisations, and policy 
makers.
Changes are required in global health 
research to ensure that co-production 
is strengthened and help overcome 
the challenges that researchers face in 
implementing it. The first obstacle is 
the pressing challenges in many LMIC 
settings, ranging from high disease burden 
to fragmented health systems, poverty, 
and inequities. These are complex and 
interconnected problems.8 Secondly, this 
complexity necessitates interdisciplinary, 
multidisciplinary, and transdisciplinary 
approaches.9 This requires the recognition 
by researchers and funders that contri-
butions from a broad spectrum of relevant 
experts and stakeholders is crucial for 
co-production9 10 and that they need to 
be included in the research process from 
the beginning. Finally, researchers need 
to work with existing partners, or identify 
possible partners, in countries and start 
adapting or developing new ideas and 
translating these into a comprehensive 
research proposal. This process also raises 
the issue of unequal power relations 
between different parties involved, in 
terms of the value placed on their ideas 
and knowledge. Overcoming these three 
challenges takes time and requires building 
trust with academic and non-academic 
partners in the funding application as 
well as multiple stakeholders beyond the 
research proposal.11 In addition, training, 
career progression, institutional decisions 
and investment, and funding processes 
need to be rethought.
Training and communication are essential
Tackling complex issues in LMICs and 
engaging in successful co-production 
requires specific training for researchers in 
global health theory, policy, and practice,5 7 
as well as increased knowledge and aware-
ness of global health issues by funders and 
reviewers. Cross-cultural awareness and 
communication skills are also needed to 
enable effective communication between 
partners from different cultural and geo-
graphical settings, as well as between 
researchers and stakeholders with different 
backgrounds from the same country. For 
example, as part of the Swiss Programme 
for Research on Global Issues for Develop-
ment (r4d programme), the Swiss National 
Science Foundation organised training on 
cultural communication, influencing pol-
icy makers, etc for researchers it funded.12 
Such training, however, should be part of 
the foundation of a researcher’s skills and 
not delivered on an ad hoc basis.
Researchers also need training to pro-
vide them with the tools and skills for 
advocacy. In parallel, the role of academic 
researchers in shaping policy also needs to 
be defined in the context of co-production. 
The link between research and advocacy 
can be straightforward when the evidence 
generated is directly linked to an issue that 
is of interest to policy makers.13 However, 
simply providing and promoting results to 
policy makers is different from researchers 
and other stakeholders advocating for the 
interests of communities.
Time, resources, and “cost”
Co-production requires more time and 
investment by researchers than traditional 
models of research,1 14 potentially taking 
time away from other academic activities. 
Beyond the time needed to actually imple-
ment co-production in the development 
and delivery of research, there is the need 
to invest in developing relationships, iden-
tifying ways of working together, conduct-
ing formative research, building a common 
language, and securing and sharing gains. 
These efforts are not adequately acknowl-
edged by institutions and funders. The out-
puts from co-production do not match the 
metrics commonly used to assess the track 
record of academics—namely, high impact 
factor publications—as they may not be a 
KEY MESSAGES
•   Researchers are being asked to co-
produce research with relevant stake-
holders, without being given the 
appropriate tools and resources to do 
this effectively
•   The research agenda and its devel-
opment and implementation should 
have more active involvement from 
lay participants, healthcare providers, 
policy makers, and other stakeholders
•   Training and funding processes need 
to be rethought and adapted to facili-
tate co-production more routinely
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standard randomised trial or suitable for 
peer reviewed publications.8
Involving stakeholders in co-production 
also has financial and non-financial 
costs for researchers, such as the time 
and “emotional” costs of explaining that 
the research will address only one of the 
many needs stakeholders might have.7 In 
many LMICs, high staff turnover among 
collaborating organisations makes it harder 
to maintain links and relationships.
In Peru, a co-creation process to 
develop an intervention to improve the 
diagnosis and management of chronic 
diseases (diabetes, hypertension, and 
neurocysticercosis), highlighted divergent 
views between different stakeholders 
and the community raised issues that 
were beyond the “intended” scope of the 
project.1 For example, the community 
priority was improving water and 
sanitation, whereas the focus of the project 
was on strengthening the health system. 
The trust developed through the project 
and the time invested in the interactions 
with stakeholders and the community 
resolved these differences and established 
common understanding.
Co-production requires having the 
appropriate skills and the resources 
to be able to focus energy on these 
activities, which are usually beyond the 
scope and duration of time-bounded 
research projects. These costs need to be 
accounted for and built into budgets and 
rules for funding to facilitate the reality of 
co-produced research in LMICs.
Platforms for exchange
Investment in creating platforms to enable 
equal exchanges facilitates relationships 
between researchers and stakeholders.6 9 
For example, the James Lind Alliance 
brings together people with specific health 
needs, carers, and clinicians to identify 
and prioritise research gaps with the aim of 
improving care.10 Other organisations have 
institutionalised this multistakeholder 
approach—for example, the UK’s National 
Institute for Health and Clinical Excellence, 
the faculty of medicine at the University of 
Montreal, and the Welsh ALPHA (Advice 
Leading to Public Health Advancement) 
group, where people representing certain 
interest groups or with a certain disease 
sit on decision making panels.15-17 Such 
platforms ensure that people with specific 
health problems can present their expertise 
and perspective2 rather than academics 
or funders setting priorities, and enables 
research to reflect societal concerns.4 These 
platforms should operate as an interface 
and allow for exchange and dissemination 
to occur between science, social organisa-
tions, and policy makers.
Platforms can also empower stake-
holders and foster the development 
of relationships and partnerships that 
facilitate power sharing and enable 
co-production.18 The example from Peru 
shows how a co-production approach 
enabled stakeholders to transition from 
key informants during the formative 
research, to active partners in co-creating 
solutions, and finally towards direct or 
indirect involvement in implementing the 
intervention they helped produce.1
Strong and equitable partnerships with 
buy-in and engagement of all partners, as 
well as funders, are the foundations of an 
effective co-production process in global 
health research. Many guidelines exist 
to help develop and foster partnerships, 
such as the 11 principles outlined by 
the Swiss Commission for Research 
Partnerships with Developing Countries.19 
In addition, tools such as the Research 
Fairness Initiative ensure due diligence in 
establishing partnerships.20 Furthermore, 
co-production itself can be seen as a tool 
for empowerment and partnerships,5 
with funders having a role in promoting 
equitable partnerships.21
Increasing evidence and uptake
Some validated approaches and guidelines 
to help direct and apply co-production pro-
cesses already exist.16 The UK’s National 
Institute for Health Research3 provides 
five principles: “Sharing power, including 
all perspectives and skills, respecting and 
valuing the knowledge of all those work-
ing together on the research, reciprocity, 
and building and maintaining relation-
ships.”22 2 1 Critics of co-production argue 
there is an absence of evidence for imple-
menting co-production and that most 
research focuses on promoting the wider 
use of co-production or reflects a theoreti-
cal discourse that is not easily translated 
into actions. More evidence about the effec-
tiveness of co-production compared with 
the usual academic approaches is lack-
ing.10 18 23 However, this discussion leads 
to a vicious cycle: if co-production is not 
considered “scientific enough” through a 
lack of evidence for funders and journals to 
support it, then the chances of funding and 
creating evidence diminish further. From 
a development perspective, co-production 
is seen as an essential tool in achieving the 
sustainable development goals,23 where 
research is needed to address a wide range 
of intermingled complex challenges. How-
ever, many development agencies’ remits 
have not included funding or support to 
research and academic institutions for 
partnering related activities.
Funders have an influential role in 
shaping the research agenda by making 
certain elements an essential part of their 
funding process—for example, public 
engagement is now part and parcel of 
research.24 With development funders 
increasingly funding research in LMICs, 
researchers will have to meet new metrics 
and requirements.25 Researchers will need 
to continuously adapt their approaches and 
CVs to meet these changes in an evolving 
funding environment. Therefore, funders 
should encourage the integration of 
co-production as an essential component of 
research to ensure that research has a larger 
impact on society, improving the health 
and wellbeing of those being “researched.”
Although the benefits of co-production 
outweigh the challenges, changes are 
needed in the conceptualisation of 
co-production in research in LMICs for this 
to become part and parcel of research with 
adequate funding (table 1). Our experience 
suggests that one important change is to 
refer to people with health conditions as 
partners in co-production not patients. 
Describing people as “patients” often 
narrows their contribution to a specific 
disease, while ignoring complexity in 
health outcomes and underplays the 
holistic views they bring as individuals.
Researchers also need protected time and 
resources to truly work in a co-productive 
way with their partners and stakeholders, 
both at the stage of developing a proposal 
and in the conduct of the research. Inno-
vations such as engagement platforms need 
to be created to enable this knowledge to be 
integrated from the outset of the research 
process. Co-produced research tends not 
to fit traditional calls for funding around 
vertical disease or specific themes or 
generate standard outputs, including 
academic publications, since it tends 
to be more horizontal in nature, scope, 
and engagement.8 26 Metrics to evaluate 
researchers and assess the successful 
implementation of co-production beyond 
high impact publications should be 
developed.
More radical rethinking would consider 
funding partnerships rather than projects. 
The concept of co-production might be 
better integrated beyond the requirements 
of a single study, instead being built 
and sustained over a range of activities 
over time under the umbrella of an 
organisational partnership. Rather than 
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expecting one project to fit the bill of a 
“perfect” co-production project, resources 
should be put into fostering a series of 
meaningful interactions with key partners 
from high income countries as well as 
LMICs, within and beyond academia. This 
would nurture co-production efforts in the 
spirit of equitable partnerships. Academic 
institutions globally will also need to 
incorporate a long term view towards 
meaningful partnerships, leading to 
institutional incentives and investment, to 
break the problem of funders continuously 
setting the agenda, turning into short lived 
partnerships.
The current challenge for researchers 
is knowing whose needs they should 
prioritise: the communities in which they 
are working, policy makers in the country 
where they are working, policy makers in 
the country funding the research, or the 
funder? Arguably, the model we operate is 
“who pays the piper calls the tune.” Change 
is required for researchers, funders, and 
stakeholders to jointly decide what tune 
will be played, and also the instrument(s) 
that are used.
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